Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release

2021 ◽  
Author(s):  
Paola Rogliani ◽  
Beatrice Ludovica Ritondo ◽  
Francesco Facciolo ◽  
Maria Gabriella Matera ◽  
Ivan Nikolaev ◽  
...  
Keyword(s):  
Acetylcholine Release ◽  
Mometasone Furoate ◽  
Glycopyrronium Bromide

scholarly journals Lung Function Normalisation with Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate in Patients with Asthma

2021 ◽  
Author(s):  
Kenneth R. Chapman ◽  
Henrik Watz ◽  
Dave Singh ◽  
Jens M. Hohlfeld ◽  
Zuzana Diamant ◽  
...  
Keyword(s):  
Lung Function ◽  
Mometasone Furoate ◽  
Glycopyrronium Bromide

scholarly journals Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada

2021 ◽  
Vol Volume 13 ◽  
pp. 957-967
Author(s):  
Mondher Mtibaa ◽  
Subhajit Gupta ◽  
Madhusubramanian Muthukumar ◽  
Jessica Marvel ◽  
Harneet Kaur ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Severe Asthma ◽  
Mometasone Furoate ◽  
Once Daily ◽  
Glycopyrronium Bromide

Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on human airway inflammation

2021 ◽  
Author(s):  
Paola Rogliani ◽  
Beatrice Ludovica Ritondo ◽  
Francesco Facciolo ◽  
Ivan Nikolaev ◽  
Luigino Calzetta
Keyword(s):  
Airway Inflammation ◽  
Mometasone Furoate ◽  
Glycopyrronium Bromide ◽  
Human Airway

The position of the fixed combination of indacaterol, glycopyrronium, and mometasone furoate in the management of bronchial asthma. The Report of Expert Panel of Russian Respiratory Society

2021 ◽  
Vol 31 (1) ◽  
pp. 66-74
Author(s):  
Z. R. Aisanov ◽  
S. N. Avdeev ◽  
A. S. Belevskiy ◽  
A. A. Vizel' ◽  
A. V. Emel'yanov ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Bronchial Asthma ◽  
Biological Therapy ◽  
Expert Panel ◽  
Mometasone Furoate ◽  
Inhalation Therapy ◽  
Full Potential ◽  
Glycopyrronium Bromide ◽  
Medical Centers ◽  
Long Acting

Achieving the control of bronchial asthma (BA) in real clinical practice remains an unresolved problem, despite the expansion of therapeutic options in this area. Guidelines about when and for whom should a particular treatment be used continue to develop. Increasing of inhaled corticosteroid dose (ICS) in combination with a long-acting β2-agonist (LABA) does not always lead to the desired result, although a combined LABA-ICS inhaler could improve the course of asthma and increase adherence. The addition of tiotropium bromide to LABA-ICS requires the use of two inhalers. The targeted biological therapy is associated with the complexity of phenotyping and is possible only in specialized medical centers. Mometasone furoate, indacaterol acetate, and glycopyrronium bromide in fixed doses were combined in Breezhaler® inhaler for asthma maintenance therapy once per day. This way of treatment helps to realize full potential of maintenance inhalation therapy of bronchial asthma and to simplify the achievement of control over the disease in routine clinical practice.

scholarly journals Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Satoru Inoue ◽  
Soniya Vaidya ◽  
Hanns-Christian Tillmann ◽  
Yohei Sakita ◽  
Surendra Machineni ◽  
...  
Keyword(s):  
Geometric Mean ◽  
Mometasone Furoate ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
High Dose ◽  
Open Label ◽  
Post Dose ◽  
Glycopyrronium Bromide ◽  
Dose Combination ◽  
Medium Dose

Abstract Background A once-daily (o.d.) fixed-dose combination of indacaterol acetate (IND), glycopyrronium bromide (GLY), and mometasone furoate (MF) delivered via the Breezhaler® device (IND/GLY/MF) is being developed for treatment of asthma. This study compared steady-state pharmacokinetics of IND, GLY and MF between Japanese and Caucasian male subjects after multiple inhalations of IND/GLY/MF o.d. Methods This was a single-center, open-label, 2-treatment crossover study with a 21-day washout period. Japanese and Caucasian subjects received IND/GLY/MF 150/50/80 μg (inhaled corticosteroid [ICS] medium-dose) or 150/50/160 μg o.d. (ICS high-dose) for 14 days in each period. Pharmacokinetics were characterized up to 24 h post-dose on Days 1 and 14. Results In total, 16 Japanese (median age 31 years [range 20–40 years], mean weight 68.3 kg) and 17 Caucasian subjects (median age 27 years [range 21–43 years], mean weight 75.0 kg) were randomized. Geometric mean ratios (Japanese/Caucasian) [90% confidence interval (CI)] for Cmax for IND, GLY and MF at the high ICS dose on Day 14 were 1.31 [1.13, 1.51] 1.38 [1.13, 1.69] and 1.07 [0.969, 1.18], respectively. Geometric mean ratios (Japanese/Caucasian) [90% CI] for AUC0–24h on Day 14 for IND, GLY and MF at the high ICS dose were 1.17 [1.01, 1.35], 1.05 [0.920, 1.20] and 1.15 [1.05, 1.27] respectively. Similar trends were noted for all components for the medium ICS dose treatment. IND/GLY/MF was safe and well tolerated; no AEs suspected to be study drug-related were observed. Conclusion Pharmacokinetics of IND, GLY and MF (high and medium dose) when delivered as a fixed-dose combination were comparable between Japanese and Caucasian subjects. The IND/GLY/MF combination at the administrated doses was safe and well tolerated in both ethnic groups. Trial registration Japan Registry of Clinical Trial: jRCT2031200227, retrospectively registered on 04, December, 2020.

Severe Drooling and Treatment With Botulinum Toxin

2012 ◽  
Vol 21 (1) ◽  
pp. 15-21
Author(s):  
Merete Bakke ◽  
Allan Bardow ◽  
Eigild Møller
Keyword(s):  
Botulinum Toxin ◽  
Side Effects ◽  
Health Risk ◽  
Flow Rate ◽  
Clinical Evidence ◽  
Acetylcholine Release ◽  
Psychosocial Problems ◽  
Rate Reduction ◽  
Local Inhibition ◽  
Surgical Treatments

Severe drooling is associated with discomfort and psychosocial problems and may constitute a health risk. A variety of different surgical and non-surgical treatments have been used to diminish drooling, some of them with little or uncertain effect and others more effective but irreversible or with side effects. Based on clinical evidence, injection with botulinum toxin (BTX) into the parotid and submandibular glands is a useful treatment option, because it is local, reversible, and with few side effects, although it has to be repeated. The mechanism of BTX is a local inhibition of acetylcholine release, which diminishes receptor-coupled secretion and results in a flow rate reduction of 25–50% for 2–7 months.

Sign in / Sign up

Export Citation Format

Share Document